Academic literature on the topic 'Drug development'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Drug development.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Drug development"

1

Mishra, Hara Prasad, Ayush Goel, Sahil Kumar, Mihir Chauhan, Mrinal Patnaik, and Imaad Rehman. "Drug development hit by war." Journal of Pharmacovigilance and Drug Research 3, no. 2 (2022): 11–15. http://dx.doi.org/10.53411/jpadr.2022.3.2.3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Jadhav, Mr Gahininath Thansing, and Mr Rahul Bhavlal Jadhav. "Drug Discovery and Development Process." International Journal of Research Publication and Reviews 5, no. 1 (2024): 1891–95. http://dx.doi.org/10.55248/gengpi.5.0124.0225.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sheela, Thorat* Sunita Patil Shubhangi Mali. "Pro-Drug Development." International Journal of Pharmaceutical Sciences 3, no. 3 (2025): 1234–43. https://doi.org/10.5281/zenodo.15019692.

Full text
Abstract:
Prodrugs can provide a flexible approach to enhance the efficacy or safety profile, as well as the poor pharmaceutical and pharmacokinetic features of potential therapeutic candidates as well as, in some situations, clinically authorized drugs. As the prodrugs are inactive form of the drugs which undergoes the metabolism it gives the formation of active compounds which is responsible for the therapeutic activity of drug. Right now the prodrug has more attention in the drug discovery and development. The current article focuses on the overview study of prodrugs like the definition, classificati
APA, Harvard, Vancouver, ISO, and other styles
4

Adukondalu, D., Rajesh Rajesh, Shaik Thaslim, E. Soumya, and M. Chandana. "Regulatory Guidelines for New Drug Development." Pharmaceutics and Pharmacology Research 4, no. 3 (2021): 01–11. http://dx.doi.org/10.31579/2693-7247/046.

Full text
Abstract:
Aim: The aim of present project work is to understand the guidelines and regulatory requirements for investigational new drug and development of new drug Objectives: The objective of current project include Need of a new drug to investigate New drug development targets Understanding the properties of new dug Required protocols for submission of new drug to regulatory authority Regulatory requirements to get approval of new drug.
APA, Harvard, Vancouver, ISO, and other styles
5

Sharma, Bhavik. "DRUG DISCOVERY AND DEVELOPMENT: AN OVERVIEW." INDIAN RESEARCH JOURNAL OF PHARMACY AND SCIENCE 7, no. 2 (2020): 2215–26. http://dx.doi.org/10.21276/irjps.2020.7.2.14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Agrawal, Shrutidevi, Narisetty Sunil Thomas, Anand Babu Dhanikula, Chaman Lal Kaul, and Ramesh Panchagnula. "Antituberculosis drugs and new drug development." Current Opinion in Pulmonary Medicine 7, no. 3 (2001): 142–47. http://dx.doi.org/10.1097/00063198-200105000-00005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

GRABOWSKI, H. G. "Issues of Drug Development: Orphan Drugs." Science 228, no. 4702 (1985): 981. http://dx.doi.org/10.1126/science.228.4702.981.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Vaalburg, Willem, N. Harry Hendrikse, and Erik F. J. de Vries. "Drug development, radiolabeled drugs and PET." Annals of Medicine 31, no. 6 (1999): 432–37. http://dx.doi.org/10.3109/07853899908998801.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Flaherty, Keith T., Dung T. Le, and Steven Lemery. "Tissue-Agnostic Drug Development." American Society of Clinical Oncology Educational Book, no. 37 (May 2017): 222–30. http://dx.doi.org/10.1200/edbk_173855.

Full text
Abstract:
The U.S. Food and Drug Administration (FDA) has approved drugs to treat patients with tumor types based on a single anatomic site, such as renal cell carcinoma or melanoma, rather than on a biomarker alone. This standard approach is based on a number of factors, including heterogeneity of drug effects in different biomarker-positive tumor types. Additionally, drug development for some drugs was primarily directed toward a specific genomic abnormality in a specific tumor type (e.g., drugs for anaplastic lymphoma kinase [ALK] fusion-positive non–small cell lung cancer). In such cases, difference
APA, Harvard, Vancouver, ISO, and other styles
10

Yamashiro, Yuichiro, Jennifer Martin, Madlen Gazarian, et al. "Drug Development." Journal of Pediatric Gastroenterology and Nutrition 55, no. 5 (2012): 506–10. http://dx.doi.org/10.1097/mpg.0b013e318272af1f.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Drug development"

1

Zhang, Huarui. "Design, synthesis and activity evaluation of novel exosome inhibitors." HKBU Institutional Repository, 2020. https://repository.hkbu.edu.hk/etd_oa/849.

Full text
Abstract:
Background: Exosomes are extracellular vesicles (EVs) that produced in the endosomal compartment of most eukaryotic cells, and have observed increasing attentions over the past decades. They play important roles in cell- to-cell communications, they can carry varieties of substances, like proteins, nucleic acids and lipids, to the target cells they encounter. These cargos could influence the function of recipient cells. This novel mode of intercellular communication is found to be of critical importance to many cellular activities. However, exosomes are involved in various diseases processes.
APA, Harvard, Vancouver, ISO, and other styles
2

Larson, Joeanna Lee. "Perinatal Drug Abuse Intervention: Policy Development for Drug Screening." ScholarWorks, 2016. https://scholarworks.waldenu.edu/dissertations/2555.

Full text
Abstract:
Perinatal drug abuse is becoming a profound issue facing the health and wellbeing of neonates. The community serviced by the project site, which lies within the boundaries of an Indian Reservation, suffers from perinatal drug abuse at a higher rate than state and federal averages. The purpose of this project was to provide the project site with a policy to consistently screen for perinatal drug abuse. Lave's theory of situational learning and the Sanford Way model for quality improvement framed this project. To guide policy development, data were compiled through a systematic review of current
APA, Harvard, Vancouver, ISO, and other styles
3

Hartmann, Neil Godfried. "Intercalative drugs in cancer chemotherapy : two approaches towards drug development." Thesis, University of Cambridge, 1988. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.292983.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Mawad, Damia Graduate School of Biomedical Engineering Faculty of Engineering UNSW. "Development of Novel hydrogels for protein drug delivery." Awarded by:University of New South Wales. Graduate School of Biomedical Engineering, 2005. http://handle.unsw.edu.au/1959.4/25221.

Full text
Abstract:
Introduction: Embolic agents are used to block blood flow of hypervascular tumours, ultimately resulting in target tissue necrosis. However, this therapy is limited by the formation of new blood vessels within the tumour, a process known as angiogenesis. Targeting angiogenesis led to the discovery of anti-angiogenic factors, large molecular weight proteins that can block the angiogenic process. The aim of this research is development of poly (vinyl alcohol) (PVA) aqueous solutions that cross-link in situ to form a hydrogel that functions as an embolic agent for delivery of macromolecular drugs
APA, Harvard, Vancouver, ISO, and other styles
5

Fagnan, David Erik. "Analytics for financing drug development." Thesis, Massachusetts Institute of Technology, 2015. http://hdl.handle.net/1721.1/98572.

Full text
Abstract:
Thesis: Ph. D., Massachusetts Institute of Technology, Sloan School of Management, Operations Research Center, 2015.<br>This electronic version was submitted by the student author. The certified thesis is available in the Institute Archives and Special Collections.<br>Cataloged from student-submitted PDF version of thesis.<br>Includes bibliographical references (pages 133-139).<br>Financing drug development has a particular set of challenges including long development times, high chance of failure, significant market valuation uncertainty, and high costs of development. The earliest stages of
APA, Harvard, Vancouver, ISO, and other styles
6

Voyi, Kuku Vinolia Vuyelwa. "Development of an antirheumatic drug." Doctoral thesis, University of Cape Town, 1988. http://hdl.handle.net/11427/17187.

Full text
Abstract:
Includes bibliographical references.<br>The diamino-diamide ligands have been investigated in an attempt to develop an antirheumatic drug. The ligands N,N'-di-(2-dimethylamino)ethyloxamide and N,N'di-(2-diethylamino)ethyloxamide, were synthesised and characterised using the physical techniques, NMR, mass- and infrared spectrometry. The stability constants of the complexes of Mg, Ca, Zn and several first transition metal-ions with the ligands were determined potentiometrically. The solution conformation of the CuII complexes were determined using visible spectrophotometry. Finally the physico-c
APA, Harvard, Vancouver, ISO, and other styles
7

Alkhaldi, Abdulsalam Abdulhadi. "Drug development against kinetoplastid parasites." Thesis, University of Glasgow, 2012. http://theses.gla.ac.uk/3637/.

Full text
Abstract:
Human African trypanosomiasis and leishmaniasis are caused by parasites belonging to the genera Trypanosoma and Leishmania, respectively. Significant numbers of people are affected by these diseases worldwide, which are fatal if untreated. Animals can also be infected, posing agricultural and economic hindrances, especially in poor countries. Although chemotherapy can be used for treatment, many problems are associated with it, including drug toxicity, resistance, lack of guaranteed supply, and high treatment cost. Therefore, there is an urgent need for new treatment approaches. Here, we aim t
APA, Harvard, Vancouver, ISO, and other styles
8

Mavridis, Lazaros. "High throughput virtual drug screening using spherical harmonic molecular surface representations." Thesis, Available from the University of Aberdeen Library and Historic Collections Digital Resources, 2009. http://digitool.abdn.ac.uk:80/webclient/DeliveryManager?application=DIGITOOL-3&owner=resourcediscovery&custom_att_2=simple_viewer&pid=25936.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Wang, Shining. "DRUG DEVELOPMENT OF TARGETED ANTICANCER DRUGS BASED ON PK/PD INVESTIGATIONS." Diss., Temple University Libraries, 2008. http://cdm16002.contentdm.oclc.org/cdm/ref/collection/p245801coll10/id/2535.

Full text
Abstract:
Pharmaceutics<br>Ph.D.<br>EGFR inhibitors, such as gefitinib, are examples of targeted anticancer drugs whose drug sensitivity is related to gene mutations that adds a pharmacogenetic [PG] dimension to any pharmacokinetic [PK] and pharmacodynamic [PD] analysis. The goal of this project was to characterize the PK/PD properties of gefitinib in tumors and then apply these results to design rational drug design regimens, and provide a foundation for future studies with EGFR inhibitors. Progressions of in vitro and in vivo studies were completed to understand the PK and PD behavior of gefitinib. In
APA, Harvard, Vancouver, ISO, and other styles
10

Alavi, Hajar Karimi. "Development of mechanistic mathematical models for gene-mediated drug-drug interactions." Thesis, University of Manchester, 2016. https://www.research.manchester.ac.uk/portal/en/theses/development-of-mechanistic-mathematical-models-for-genemediated-drugdrug-interactions(b38da88a-bb2a-4667-9809-21a09c8feeeb).html.

Full text
Abstract:
The glucocorticoid receptor (GR) is a member of the nuclear hormone receptors family and has been shown to exert significant effects on the induction of cytochrome P450 (CYP) enzymes responsible for the metabolism of many xenobiotics. CYP3A4/5 and CYP2C9 are important CYP enzymes which metabolise more that 60% of drugs. Induction or inhibition of the enzymatic activity and the levels of these enzymes can have significant effects on drug metabolism. Understanding the role of GR and other nuclear receptors, pregnane X receptor (PXR) and the constitutive androstane receptor (CAR), in the mechanis
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Drug development"

1

Gaginella, Timothy S., and Antonio Guglietta, eds. Drug Development. Humana Press, 2000. http://dx.doi.org/10.1007/978-1-59259-202-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

E, Hamner Charles, ed. Drug development. 2nd ed. CRC Press, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

C, Rogge Mark, and Taft David R, eds. Preclinical drug development. Taylor & Francis, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Dikshit, Madhu, ed. Drug Discovery and Drug Development. Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-15-8002-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

G, Welling Peter, Lasagna Louis 1923-, and Banakar Umesh V. 1956-, eds. The drug development process. M. Dekker, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

C, Rogge Mark, and Taft David R, eds. Preclinical drug development. 2nd ed. Informa Healthcare, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

De Clercq, Erik, and Richard T. Walker, eds. Antiviral Drug Development. Springer US, 1988. http://dx.doi.org/10.1007/978-1-4684-7275-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Mulberg, Andrew E., Dianne Murphy, Julia Dunne, and Lisa L. Mathis, eds. Pediatric Drug Development. John Wiley & Sons Ltd., 2013. http://dx.doi.org/10.1002/9781118312087.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Giordanetto, Fabrizio Giordanetto, ed. Early Drug Development. Wiley-VCH Verlag GmbH & Co. KGaA, 2018. http://dx.doi.org/10.1002/9783527801756.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Cayen, Mitchell N., ed. Early Drug Development. John Wiley & Sons, Inc., 2010. http://dx.doi.org/10.1002/9780470613191.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Drug development"

1

Upchurch Sweeney, C. Renn, J. Rick Turner, J. Rick Turner, et al. "Drug Development." In Encyclopedia of Behavioral Medicine. Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4419-1005-9_100513.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Duda-Seiman, Corina, Daniel Duda-Seiman, and Mihai V. Putz. "Drug Development." In New Frontiers in Nanochemistry. Apple Academic Press, 2020. http://dx.doi.org/10.1201/9780429022951-10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Guan, Zhi-Zhong, Yi Zhao, and Chang-Xue Wu. "Drug Development." In Coal-burning Type of Endemic Fluorosis. Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-16-1498-9_25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Schmidt, Marco F. "Drug Development." In Chemical Biology. Springer Berlin Heidelberg, 2022. http://dx.doi.org/10.1007/978-3-662-64412-6_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Mahato, Ram I., Ajit S. Narang, and Virender Kumar. "Drug Development." In Pharmaceutical Dosage Forms and Drug Delivery, 4th ed. CRC Press, 2024. http://dx.doi.org/10.1201/9781003389378-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Wallace, John L. "The Arachidonic Acid Pathway." In Drug Development. Humana Press, 2000. http://dx.doi.org/10.1007/978-1-59259-202-9_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Tepperman, B. L., and B. J. R. Whittle. "Therapeutic Implications of the Nitric Oxide Pathway in Gastrointestinal Diseases." In Drug Development. Humana Press, 2000. http://dx.doi.org/10.1007/978-1-59259-202-9_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Levine, Alan D., and Claudio Fiocchi. "Cytokines." In Drug Development. Humana Press, 2000. http://dx.doi.org/10.1007/978-1-59259-202-9_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Guglietta, Antonio, and Marija Veljača. "Peptide Growth Factors in Gastrointestinal Disorder Therapeutics." In Drug Development. Humana Press, 2000. http://dx.doi.org/10.1007/978-1-59259-202-9_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Holzer, Peter. "Tachykinins." In Drug Development. Humana Press, 2000. http://dx.doi.org/10.1007/978-1-59259-202-9_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Drug development"

1

Hande, Akash, and Nikhita Chambhare. "Drug Discovery and Development Process." In 2024 2nd DMIHER International Conference on Artificial Intelligence in Healthcare, Education and Industry (IDICAIEI). IEEE, 2024. https://doi.org/10.1109/idicaiei61867.2024.10842909.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Quraishi, Aadam, Ali Hamid AbdulHussein, Maki Mahdi Abdulhasan, Ahmed Shihab Ahmed, Adnan Allawi Ftaiet, and Bhavani Prasad Kasaraneni. "Computer Aided Drug Design for Enhanced Drug Discovery and Development Processes." In 2025 4th OPJU International Technology Conference (OTCON) on Smart Computing for Innovation and Advancement in Industry 5.0. IEEE, 2025. https://doi.org/10.1109/otcon65728.2025.11070716.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Mahameed, Ans Ibrahim, Fatima Ayad Abd Al Zahraa, Ahmed Bahaaulddin A.Alwahhab, et al. "Machine Learning for Drug Discovery and Development." In 2025 7th International Congress on Human-Computer Interaction, Optimization and Robotic Applications (ICHORA). IEEE, 2025. https://doi.org/10.1109/ichora65333.2025.11017119.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Pace, Joshua, Nicole Rueb, Gauri Malankar, et al. "Development and Evaluation of Fluorescence Contrast Agents for in Vivo Counting of Circulating Cancer Cells." In Optical Molecular Probes, Imaging and Drug Delivery. Optica Publishing Group, 2025. https://doi.org/10.1364/omp.2025.oth1d.4.

Full text
Abstract:
The goal of this research is to develop a method to label and detect circulating tumor cells in vivo with different types of injectable cell targeted fluorescent molecular contrast agents while limiting immune cell labeling.
APA, Harvard, Vancouver, ISO, and other styles
5

Aneesh, Ch, Gembali Saumik, K. V. V. Varun, Rajesh M, and Sreevidya B. "Predictive Analytics for Anticipating Adverse Drug Reactions to ameliorate Drug Development and Prescription Practices." In 2024 Second International Conference on Inventive Computing and Informatics (ICICI). IEEE, 2024. http://dx.doi.org/10.1109/icici62254.2024.00037.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Moya-Lopez, Carmen, Carlos Alonso-Moreno, Inmaculada Posadas, et al. "DRUG DISCOVERY AND DEVELOPMENT (D3): A BLENDED INTENSIVE PROGRAM TO ENGAGE STUDENTS IN THE DRUG DISCOVERY PROCESS WHILE PROMOTING INTERNATIONAL COLLABORATION." In 19th International Technology, Education and Development Conference. IATED, 2025. https://doi.org/10.21125/inted.2025.1174.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Shojaee, Melika, Masoud Saeed, Fatemeh Asadi-Zeydabadi, and Mohammad Alipoor. "OptiRecDrug Application Development for OCR-Based Drug Identification." In 2024 19th Iranian Conference on Intelligent Systems (ICIS). IEEE, 2024. https://doi.org/10.1109/icis64839.2024.10887494.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Warokar, Payal, and Sukeshini Lote. "Ethical and Regulatory Consideration in AI-Assisted Drug Development." In 2024 2nd DMIHER International Conference on Artificial Intelligence in Healthcare, Education and Industry (IDICAIEI). IEEE, 2024. https://doi.org/10.1109/idicaiei61867.2024.10842700.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Pompa, Marcello, Dániel András Drexler, Simona Panunzi, et al. "Modeling the development of drug resistance during chemotherapy treatment." In 2024 IEEE 63rd Conference on Decision and Control (CDC). IEEE, 2024. https://doi.org/10.1109/cdc56724.2024.10886423.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Wu, Qi, Xuezhong Wang, and Jianguo Cao. "Intelligent Automated Parallel Crystallization Platform for Crystalline Drug Development." In 2024 6th International Symposium on Robotics & Intelligent Manufacturing Technology (ISRIMT). IEEE, 2024. https://doi.org/10.1109/isrimt63979.2024.10875315.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Drug development"

1

Basu, Sayani. Pharmacognosy in Drug Development. Spring Library, 2021. http://dx.doi.org/10.47496/nl.blog.23.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Seol, Dai-Wu. TRAIL-Based Anticancer Drug Development. Defense Technical Information Center, 2002. http://dx.doi.org/10.21236/ada407205.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Tignor, Gregory H. Drug Development against Viral Diseases. Defense Technical Information Center, 1987. http://dx.doi.org/10.21236/ada201949.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Krieger, Joshua, Danielle Li, and Dimitris Papanikolaou. Missing Novelty in Drug Development. National Bureau of Economic Research, 2018. http://dx.doi.org/10.3386/w24595.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Novotny, Jaroslav F. Preparation of Bulk Drug for the U.S. Army Drug Development Program. Defense Technical Information Center, 2004. http://dx.doi.org/10.21236/ada425622.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Novotny, Jaroslav. Preparation of Bulk Drug for the U.S. Army Drug Development Program. Defense Technical Information Center, 2001. http://dx.doi.org/10.21236/ada392524.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Novotny, Jaroslav. Preparation of Chemicals and Bulk Drug Substance for the U.S. Army Drug Development Program. Defense Technical Information Center, 2000. http://dx.doi.org/10.21236/ada382468.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Novotny, Jaroslav F. Preparation of Chemicals and Bulk Drug Substances for the U.S. Army Drug Development Program. Defense Technical Information Center, 1997. http://dx.doi.org/10.21236/adb232976.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Chandra, Amitabh, Craig Garthwaite, and Ariel Dora Stern. Characterizing the Drug Development Pipeline for Precision Medicines. National Bureau of Economic Research, 2017. http://dx.doi.org/10.3386/w24026.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Collington, Rosie, and William Lazonick. Pricing for Medicine Innovation: A Regulatory Approach to Support Drug Development and Patient Access. Institute for New Economic Thinking Working Paper Series, 2022. http://dx.doi.org/10.36687/inetwp176.

Full text
Abstract:
The United States represents the world’s largest market for pharmaceutical drugs. It is also the only advanced economy in the world that does not regulate drug prices. There is no upper threshold for the prices of medicines in the United States. List prices are instead set by manufacturers in negotiation with supply-chain intermediaries, though some federal programs have degrees of discretion in price determinations. In practice, this deregulated system means that drug prices in the United States are generally far higher than in other advanced economies, adversely affecting patient accessibili
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!